Stentys’ board of directors has appointed Michael Lesh, MD, as a director, effective immediately.
Since 2004, Lesh has served as chairman and CEO of Evera Medical, one of four companies he has founded, the company said. His first venture, Atrionix, a developer of an ultrasound ablation catheter for atrial fibrillation, was acquired by Johnson & Johnson.
He established Mitralife, a developer of a catheter-based treatment for mitral valve disease and coronary heart failure, which was acquired by ev3. Lesh also founded Appriva Medical, developer of PLAATO, a percutaneous transcatheter device for preventing stroke, which was acquired by ev3.
The Paris-based Stentys is developing a next-generation drug-eluting stent for treatment of blocked coronary artery bifurcations.